BISOPROLOL IN THE TREATMENT OF CHRONIC HEART FAILURE


M.Yu. Ogarkov (1), Yu. V. Kovaleva (1), T.A. Mulerova (2)

(1) SBEI FPE “Novokuznetsk State Institute of Advanced Training of Physicians” of RMH, Novokuznetsk; (2) FSBIS “Scientific Research Institute of Complex Problems of Cardiovascular Diseases”, Kemerovo
Beta-blockers, together with angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists, and a number of other groups of drugs used in certain clinical situations, make the maximum contribution to the optimization of prognosis in chronic heart failu-re (CHF). High-selective amphophilous drug bisoprolol was the first representative of the β-blockers with proven positive effect on the prognosis of heart failure according to the results of randomized multicenter trial. CIBIS Research Program has demonstrated the ability of the bisoprolol to reduce mortality and rate of hospitalizations in chronic heart failure of various severity, regardless of the etiology of the disease, gender and age of the patient.

About the Autors


Corresponding author: M.Yu. Ogarkov – MD, Prof., Head of the Department of Cardiology SBEI FPE “Novokuznetsk State Institute of Advanced Training of Physicians” of RMH, Novokuznetsk, tel. 8 (3843) 32-45-29, e-mail: ogarmu@kemcardio.ru


Similar Articles


Бионика Медиа